GlassScriptPhysician profile
Mackenzie Ann Warner
NPI 1982201091
$3,992.34
in general payments reported to CMS, 2019-2025
35 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $481 · 2023: $1,692 · 2024: $1,354 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $477.27 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $412.66 | 2023-2025 | |
| Glaxosmithkline, LLC. | $365.59 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.23 | 2022-2024 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $225.23 | 2022-2024 | Rexulti |
| Amgen INC. | $212.92 | 2022-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $207.46 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $181.96 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3, Eterna |
| Optinose US, INC. | $166.97 | 2023-2025 | |
| Astellas Pharma US INC | $159.07 | 2022-2024 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $152.48 | 2023-2025 | Cuvitru, Trintellix |
| Abbvie INC. | $125.20 | 2022-2024 | |
| Lilly USA, LLC | $114.42 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $109.68 | 2023-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $107.15 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.62 | 2022-2024 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $78.79 | 2022-2023 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $66.20 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $57.98 | 2022-2024 | Quviviq |
| Ars Pharmaceuticals Operations, INC. | $44.00 | 2025 | Neffy |
| Dynavax Technologies Corporation | $43.88 | 2024 | Heplisav-B |
| Exact Sciences Corporation | $43.46 | 2023-2024 | Cologuard Collection Kit |
| Genzyme Corporation | $42.76 | 2024-2025 | |
| Dexcom, INC. | $32.87 | 2023 | Dexcom G6 Transmitter |
| Csl Behring | $28.80 | 2025 | Hizentra |
| Sumitomo Pharma America, INC. | $27.71 | 2024 | Gemtesa |
| Biogen, INC. | $24.65 | 2025 | Spinraza |
| Corcept Therapeutics | $23.34 | 2024 | Korlym |
| Vivus LLC | $19.64 | 2024 | Qsymia |
| Noven Therapeutics, LLC | $19.35 | 2023 | Secuado |
| Kowa Pharmaceuticals America, INC. | $18.75 | 2023 | Seglentis, Livalo |
| Nevro Corp. | $18.07 | 2023 | Senza |
| Azurity Pharmaceuticals, INC. | $17.86 | 2024 | Horizant |
| Esperion Therapeutics, INC. | $16.96 | 2022 | |
| Pharming Healthcare, INC. | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.